Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer LJV', Esserman L, Rugo HS. Huppert LA, et al. Among authors: heditsian d. Ann Oncol. 2024 Oct 28:S0923-7534(24)04070-5. doi: 10.1016/j.annonc.2024.10.018. Online ahead of print. Ann Oncol. 2024. PMID: 39477071
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Shatsky RA, et al. Among authors: heditsian d. Nat Med. 2024 Sep 14. doi: 10.1038/s41591-024-03267-1. Online ahead of print. Nat Med. 2024. PMID: 39277672
Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
Northrop A, Christofferson A, Umashankar S, Melisko M, Castillo P, Brown T, Heditsian D, Brain S, Simmons C, Hieken T, Ruddy KJ, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Asare A, Esserman L, Hershman DL, Basu A. Northrop A, et al. Among authors: heditsian d. J Am Med Inform Assoc. 2024 Aug 19:ocae190. doi: 10.1093/jamia/ocae190. Online ahead of print. J Am Med Inform Assoc. 2024. PMID: 39158353
18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, Jones EF, Ray KM. Diwanji D, et al. Among authors: heditsian d. Radiol Imaging Cancer. 2024 Mar;6(2):e230082. doi: 10.1148/rycan.230082. Radiol Imaging Cancer. 2024. PMID: 38551406 Free PMC article.
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
Parikh DA, Kody L, Brain S, Heditsian D, Lee V, Curtis C, Karin MR, Wapnir IL, Patel MI, Sledge GW Jr, Caswell-Jin JL. Parikh DA, et al. Among authors: heditsian d. Breast Cancer Res Treat. 2022 Jul;194(1):171-178. doi: 10.1007/s10549-022-06611-6. Epub 2022 May 11. Breast Cancer Res Treat. 2022. PMID: 35538268 Free PMC article.
The WISDOM study: a new approach to screening can and should be tested.
Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M. Esserman L, et al. Among authors: heditsian d. Breast Cancer Res Treat. 2021 Oct;189(3):593-598. doi: 10.1007/s10549-021-06346-w. Epub 2021 Sep 16. Breast Cancer Res Treat. 2021. PMID: 34529196 No abstract available.
Rationale, Study Design, and Cohort Characteristics for the Markers for Environmental Exposures (MEE) Study.
Lucia RM, Huang WL, Alvarez A, Thampy D, Elyasian M, Hidajat A, Yang K, Forman D, Pebdani A, Masunaka I, Brain S, Heditsian D, Lee V, Goodman D, Norden-Krichmar TM, Odegaard AO, Ziogas A, Park HL. Lucia RM, et al. Among authors: heditsian d. Int J Environ Res Public Health. 2020 Mar 9;17(5):1774. doi: 10.3390/ijerph17051774. Int J Environ Res Public Health. 2020. PMID: 32182891 Free PMC article.
13 results